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The major vault protein is the main component on multimeric vault particles, that are likely to play an essential role in normal
cell physiology and to be associated with multidrug resistance of tumour cells. In order to unravel the function of vaults and
their putative contribution to multidrug resistance, speciﬁc antibodies are invaluable tools. Until now, only conventional major
vault protein-reactive murine monoclonal antibodies have been generated, that are most suitable for immunohistochemical
analyses. The phage display method allows for selection of human antibody fragments with potential use in clinical applications.
Furthermore, cDNA sequences encoding selected antibody fragments are readily identiﬁed, facilitating various molecular
targeting approaches. In order to obtain such human Fab fragments recognising major vault protein we used a large non-
immunized human Fab fragment phage library. Phages displaying major vault protein-reactive Fabs were obtained through
several rounds of selection on major vault protein-coated immunotubes and subsequent ampliﬁcation in TG1 E coli bacteria.
Eventually, one major vault protein-reactive clone was selected and further examined. The anti-major vault protein Fab was
found suitable for immunohistochemical and Western blot analysis of tumour cell lines and human tissues. BIAcore analysis
showed that the binding afﬁnity of the major vault protein-reactive clone almost equalled that of the murine anti-major vault
protein Mabs. The cDNA sequence of this human Fab may be exploited to generate an intrabody for major vault protein-
knock out studies. Thus, this human Fab fragment should provide a valuable tool in elucidating the contribution(s) of major
vault protein/vaults to normal physiology and cellular drug resistance mechanisms.
British Journal of Cancer (2002) 86, 954–962. DOI: 10.1038/sj/bjc/6600159 www.bjcancer.com
ã 2002 Cancer Research UK
Keywords: LRP; MVP; multidrug resistance; Fab; phage display.
Multidrug resistance (MDR; reviewed in Schneider et al, 1999) is a
phenomenon frequently observed in tumour cells that are unre-
sponsive to anti-cancer drugs. Proteins which can be involved in
this process are the ATP-binding Cassette (ABC) transporter
proteins (Higgins, 1992) P-glycoprotein (P-gp, ABCB1; reviewed
in Ambudkar et al, 1999), multidrug resistance protein 1 (MRP1,
ABCC1), MRP2 (ABCC2), MRP3 (ABCC3; reviewed in Borst et
al, 2000) and breast cancer resistance protein (BCRP, ABCG2;
Doyle et al, 1998), as well as the lung resistance-related protein
(LRP; Scheffer et al, 2000). LRP was identiﬁed as the major vault
protein (MVP), the main component of vaults (Scheffer et al,
1995).
Vaults are large multimeric barrel-shaped particles that are
highly conserved through evolution, and likely to play an essential
role in normal cell physiology. They are composed of multiple
copies of three proteins (240, 193 and 104 kDa in size) and
unique untranslated RNA species. The 104 kDa subunit is termed
the MVP as it constitutes 470% of the particle mass. The p240
minor vault protein is identical to the telomerase-associated
protein (TEP1) (Kickhoefer et al, 1999a), a structural protein in
the telomerase complex. The other high molecular weight minor
vault protein, p193, is a poly (ADP-ribose) polymerase (PARP)
and is therefore named VPARP, for vault-PARP (Kickhoefer et
al, 1999b).
The hollow structure of vaults is consistent with a role in either
the compartmentalisation of macromolecular assemblies or in
subcellular transport. In multidrug resistant tumour cells up-regu-
lation of human LRP/MVP mRNA and protein as well as vault
particle copy number was observed (Scheper et al, 1993; Laurencot
et al, 1997; Kickhoefer et al, 1998). Primary evidence for a direct
causal relationship between LRP/MVP expression and drug resis-
tance was provided by Kitazono et al (1999). They showed that
reduction of LRP/MVP expression by use of LRP/MVP-speciﬁc
ribozymes in a cell line induced to overexpress LRP/MVP by expos-
ing cells to sodium butyrate was enough to prevent drug resistance.
Still, these studies have to be conﬁrmed by independent investiga-
tions.
In order to further study the function of vaults and their contri-
bution to MDR, speciﬁc antibodies are essential. Several MVP-
reactive murine monoclonal antibodies (Mabs) are now available.
These Mabs were all produced by classical hybridoma technology.
In the past years the technology of display on ﬁlamentous phage
in combination with selection was developed into a powerful tool
for the identiﬁcation of antibodies of human origin (Marks et al,
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completely human antibodies are of particular interest as they
are expected to elicit no or minimal immune responses when
administered to patients. For the construction of antibody libraries,
V-genes are ampliﬁed from B-cell cDNA, and heavy and light chain
genes are randomly combined and cloned to encode a combinator-
ial library of single-chain variable fragments (scFv) or Fab antibody
fragments (Clackson et al, 1991; Hoogenboom et al, 1991). Large
non-immune human antibody libraries, made for example from
the variable region genes of the B-cells of healthy individuals, have
been used to select antibodies to a large panel of antigens, includ-
ing self-, non-immunogenic- and relatively toxic antigens (Marks et
al, 1991; de Haard et al, 1999). When using the phage display
system, the cDNA of antibodies of interest becomes available with-
out further cloning steps. In this study we used a large non-
immunised human Fab fragment phage library described by de
Haard et al (1999) to isolate a human Fab reactive to the MVP.
MATERIALS AND METHODS
Escherichia coli strain
Escherichia coli TG1: K12, D(lac-pro), supE, thi, hsdD5/F’ traD36,
proA
+B
+, lacl
q, lacZDM15.
Selection of phages displaying anti-MVP human Fab
For the selection of phages expressing anti-MVP Fab fragments a
large non-immunised human Fab fragment phage library was used
which was described by de Haard et al (1999). The library contains
cDNA sequences, encoding highly diverse Fab fragments
(3.7610
10) with additional c-myc and His tags, cloned in the
phagemid vector pCES1.
Selection of phages was essentially according to published meth-
ods (Marks et al, 1991) on immunotubes (Nunc maxisorp; Life
Technologies, Merelbeke, Belgium) coated overnight at 378C with
20 mg recombinant full-length MVP (Schroeijers et al, 2000) in
2 ml coating buffer (0.05 M sodium carbonate, pH 9.6). Unbound
antigen was removed and the tubes were blocked for 1 h with PBS/
2% skimmed milk powder/0.05% Tween 20 (MT–PBS). One ml of
the page stock solution containing approximately 1610
13 phages
was diluted 1:1 in MT–PBS and allowed to bind to the anti-
gen-coated immunotube for 2 h at room temperature. Unbound
phages were washed off by 20 washes with PBS/0.05% Tween 20
followed by 20 washes with PBS. Antigen-bound phages were
eluted off, using 1 ml freshly prepared 100 mM triethylamine
(TEA) for 10 min. The solution was neutralised by adding 0.5 ml
of Tris buffer (1 M, pH 7.4). The solution was incubated for
another hour at room temperature on immunotubes coated only
with block buffer, to remove aspeciﬁcally bound phages. Unbound,
antigen-speciﬁc phages were used to infect exponentially growing
(OD600 of 0.5) TG1 bacteria, for 30 min at 378C. After infection,
the bacteria were allowed to grow overnight at 308C and glycerol
stocks were made. To have an indication of the phage input/output
ratio, titrations of the bacteria, immediately after infection, were
plated on selective 26TY (16 g l
71 trypton, 10 g l
71 yeast extract
and 5 g l
71 NaCl) plates supplemented with 2% glucose and
100 mgm l
71 ampicillin. The plates were incubated overnight at
308C and colonies were counted the following day. For the next
selection round, a sufﬁcient amount of bacteria to ensure the
presence of at least 10 bacteria of each clone, was inoculated in
50 ml 26TY medium containing 100 mgm l
71 ampicillin and
2% glucose, giving a start OD600 of approximately 0.05. Five ml
of bacteria grown at 378Ct oa nO D 600 of 0.5 were infected with
2 ml M13-K07 helper phage (approximately 1610
13 phages per
ml) for 30 min at 378C. The bacteria were spun down, resuspended
in 50 ml of 26TY medium containing 100 mgm l
71 ampicillin and
25 mgm l
71 kanamycin to select for super-infected bacteria, and
grown overnight at 308C. The bacteria were spun down, the
selected phages secreted into the supernatant were precipitated
twice using 1/5th volume 20% PEG 6000; 2.5 M NaCl, resuspended
in 1 ml of PBS and used in the next selection round on antigen
coated immunotubes. A total of four, essentially identical selection
rounds was carried out on MVP-coated immunotubes.
Screening of individual phage clones
To select individual phage clones displaying MVP-reactive Fabs,
single bacterial colonies were grown at small-scale overnight at
308Ci n2 6TY/2% glucose/100 mgm l
71 ampicillin in U-shaped
96-well plates (Costar, Corning, NY, USA). These plates were kept
as ‘master plates’ at 7808C after adding glycerol to a ﬁnal concen-
tration of 15%. Then, 1:100 dilutions of the bacterial colonies
were grown for 2 h at 378C in V-shaped 96-well plates (Costar).
Phages displaying recombinant Fab were produced by adding
25 ml of 1:250 diluted helper phage stock solution. Supernatants
containing phages were tested for reactivity in recombinant MVP
coated ELISA plates. ELISA plates were coated overnight at 378C
with 100 ml, 5 mg MVP per ml coating buffer (0.05 M sodium
carbonate, pH 9.6). Plates were rinsed, blocked with 200 ml PBS/
1% BSA/0.05% Tween 20 and incubated with phage-containing
supernatant for 1 h at room temperature. Bound phages were
detected using an in-house produced guinea pig-anti-phage poly-
clonal antiserum (1:1000) and HRP-labelled swine–anti-guinea
pig antiserum (1:500, Dako, Copenhagen, Denmark). Colour
development was with 5-amino-2-hydroxybenzoic acid (5-AS;
Merck, Darmstadt, Germany) and 0.02% H2O2 as a chromogen.
Large-scale production of Fab fragments
Large-scale induction of soluble Fabs from individual clones was
performed on a 50 ml scale in 26TY medium, containing
100 mgm l
71 ampicillin and 2% glucose. The bacteria were grown
at 378Ct oa nO D 600 of 0.9. The cells were pelleted, resuspended in
50 ml 26TY, containing 100 mgm l
71 ampicillin and 1 mM
isopropyl-1-thio-b-D-galactopyranoside (IPTG) to activate the LacZ
promoter, and grown for 4 h at 308C. Soluble Fabs were puriﬁed
making use of the His-tag on Ni-NTA-superﬂow agarose beads
according to the manufacturer’s protocol (Qiagen Inc., CA, USA).
BstNI ﬁngerprinting
Individual bacterial colonies were used for standard 40 cycle hot-
start PCR reactions, using fd-tet-seq24 (5'-TTT GTC GTC TTT
CCA GAC GTT AGT-3') as a forward and M13-reverse (5'-AGC
GGA TAA CAA TTT CAC ACA GG-3') as a reverse primer. The
resulting amplimers were digested with BstNI and loaded onto a
2% agarose gel. The banding pattern of the clones was analysed
on a UV transluminator.
Sequence analysis
Plasmids from individual bacterial clones were sequenced using the
dideoxy sequencing method on a semi-automated sequencer (Alf
Express, Pharmacia, Uppsala, Sweden). CH1 for (5'-GTC CTT
GAC CAG GCA GCC CAG GGC-3') and M13 reverse (5'-AGC
GGA TAA CAA TTT CAC ACA GG-3') were used as forward
and reverse primers, respectively. V-gene sequences were
aligned to V-BASE (http://www.mrc-cpe.cam.ac.uk/imt-doc/
public/INTRO.html).
Immunoprecipitation
Cells were trypsinised and lysed in PBS containing 1% NP40, 1 mM
EDTA, 1 mM phenylmethylsulphonyl ﬂuoride (PMSF) for 2 min at
room temperature, followed by a boost with an ultra-sound ﬁnger.
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
A phage-displayed Fab reactive to MVP
GL Scheffer et al
955
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(6), 954–962Large fragments and nuclei were removed by centrifugation at 9000
g. Clear supernatant was pre-incubated for 30 min with protein A-
sepharose beads to reduce non-speciﬁc binding of labelled protein.
Cell lysate supernatants or solutions containing approximately
10 mg recombinant MVP were incubated with 10 ml soluble Fab
or, as a control, 10 mg of LRP-56 MAb 2 h at room temperature.
To the Fab precipitation 100 ml of anti-c-myc mouse monoclonal
antibody 9E10 was added and incubation was continued for
another hour. Then 50 ml of prot A-sepharose beads (*25 ml
‘packed beads’) was added and precipitation was allowed for 1 h.
Precipitates were washed three times in lysis buffer and three times
in PBS. Antibody–antigen interaction was broken by dispensing
the beads in Western blot loading buffer, containing 200 mM
Tris-HCl (pH 6.8), 1% b-mercaptoethanol, 8% SDS, 10% glycerol
and 0.05% bromophenol blue.
Western blot analysis
Total cell lysates were made as described (Zaman et al, 1994).
Protein concentrations were determined with a BioRad protein
assay (BioRad, Richmond, CA, USA). Cell lysates (10–40 mg)
or 2 mg recombinant MVP or immunoprecipitates were fractio-
nated on a 8% polyacrylamide slab gel and transferred onto a
nitrocellulose membrane by electroblotting. After blocking, the
membrane was incubated for 2 h with anti-MVP Fab in an
appropriate dilution. HRP-labelled rabbit–anti-human lambda
chain (1:200, Dako) was used as a secondary antibody. Colour
development was with 0.5 g l
71 3,3'-diamino-benzidine tetra-
hydrochloride, 0.15 g l
71 chloronaphthol and 0.02% H2O2 in
PBS.
BIAcore analysis
The afﬁnity of the anti-MVP antibodies was further examined by
surface plasmon resonance on a BIAcore 2000 instrument (Biacore
AB, Uppsala, Sweden). Recombinant fusion protein of MVP and
glutathione-S-transferase (GST–MVP; Schroeijers et al, 2000) was
immobilised on the ﬂow cell of an activated CM-5 sensorchip
according to the manufacturer’s protocol (Biacore AB), yielding a
surface of 2000 resonance units. Soluble Fab fragments and control
murine Mabs were analysed at room temperature, at a ﬂow rate of
25 ml per minute, using HBS-EP (Biacore AB, 0.01 M HEPES,
pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% polysorbate 20) as a
buffer. Dissociation rates were calculated from the sensorgrams
using the BIA-evaluation software (Biacore AB).
Immunohistochemistry
Cytospin preparations and cryosections (4 mm) were air dried
overnight and ﬁxed at room temperature for 7 min in 100%
acetone or for 10 min in 3% paraformaldehyde/0.3% glucose.
For detection of MVP with MVP-37 Mab and human Fab MVP-
j4, the slides were pretreated with 6 N guanidine hydrochloride
Fab MVP-j4, the slides were pretreated with 6 N guanidine hydro-
chloride (GdnHCl) in 50 mM Tris-HCl (pH 7.5) for 10 min at
room temperature, as described (Schroeijers et al, 2000). The slides
were incubated with primary antibody for 1 h at room temperature
or at 378C for the GdHCl treated slides. Biotinylated rabbit-anti-
mouse (1:150, Zymed, San Francisco, CA, USA) and HRP-labelled
streptavidin (1:500, Zymed) were used as secondary reagents for
the mouse Mabs. For detection of the human Fab, 1:10 diluted
anti-c-myc-tag 9E10 Mab, and HRP-labelled rabbit-anti-mouse
serum (1:500, Dako, Copenhagen, Denmark) was used.
Colour development was with 0.4 mg ml
71 amino-ethyl-carba-
zole (AEC) and 0.02% H2O2 as a chromogen.
Cell lines
The lung cancer cell lines SW1573 (parent), SW1573/2R120 (MVP
and MRP1 positive), SW1573/2R160 (MDR1 P-gp positive and a
low percentage of MVP positive cells) were described in reference
(Kuiper et al, 1990). The lung cancer cell lines GLC4 (parent)
and GLC4/ADR (MVP and MRP1 positive) were described in
reference (Zijlstra et al, 1987). All cell lines were grown in Dulbec-
co’s modiﬁed essential medium (Gibco Europe, Paisley, Scotland),
supplemented with 10% heat-inactivated foetal calf serum, 2 mML -
glutamine, penicillin and streptomycin. Resistant cell lines were
cultured in the presence of drugs until 3–10 days before the
experiments. All cells were negative for Mycoplasma as tested by
the Gene-Probe rapid Mycoplasma detection system (Gene-Probe,
San Diego, CA, USA).
Antibodies
Murine anti-MVP Mabs used were LRP-56 (Scheper et al, 1993),
LMR-5 (Flens et al, 1997), MVP-9, MVP-16, MVP-37 (Schroeijers
et al, 2001) and LRP (Transduction Laboratories, Lexington, KY,
USA).
The anti-c-myc mouse Mab 9E10 was described in Chan et al
(1987). The guinea pig-anti-phage polyclonal antiserum was
produced by immunizing guinea pigs with wild type M13-K07
helper phages suspended in Freund’s complete adjuvant (Difco,
Detroit, MI, USA). Two booster injections with phages in PBS were
given. Serum was collected and used without further puriﬁcation.
RESULTS
Selection of anti-MVP human Fab
The successive rounds to select anti-MVP human Fabs on immu-
notubes coated with recombinant MVP, showed a gradual
increase in the amount of antigen bound phages (output number).
When the output number of round one was set to 1, output
numbers of 50, 500 and 10000 were noted for round 2, 3 and 4,
respectively (Table 1). Apparently, the cycles of selection and re-
amplication yielded increasing numbers of antigen-binding phages.
ELISA screening of approximately 750 individual clones from
round 2, 3 and 4, resulted in the identiﬁcation of several MVP-
reactive phages. The percentage of antigen binding phages per
selection round is depicted in Table 1. Twenty-two individual
MVP-reactive clones from round 3 and 4 were selected for BstNI
ﬁngerprinting. These clones all showed a very similar banding
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Table 1 Enrichment of MVP binding phages per selection round
Input phages Output Input/output Enrichment Enrichment Recombinant MVP
10
13 per ml phages ratio per round factor ELISA positives
1st round 1610
4 1610
9 1
2nd round 5610
5 2610
7 50 50 0/48
3rd round 5610
6 2610
6 10 500 15/224
4th round 1610
8 1610
5 20 10000 18/440
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Irrelev. clone
marker
Figure 1 BstNI ﬁngerprinting of six MVP-reactive clones from selection rounds 3 and 4 and a randomly selected non-reactive clone. cDNA of individual
clones was PCR ampliﬁed, BstNI digested and loaded on an agarose gel. The MVP-reactive clones all show a very similar banding pattern, strikingly different
from the irrelevant clone.
Figure 2 Comparison of the obtained heavy chain cDNA sequence of the anti-MVP Fab MVP-j4 (accession number AJ306838) with V-BASE. The Fab
uses a heavy chain belonging to the VH4 family. Highest homology was observed to germline clone DP-66/V71-2...+. The antigen speciﬁc CDR3 sequences
for the heavy chain are: QGVYYYYGMDV. The number of amino acid changes from the germline, excluding the CDR3 region, is eight.
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Figure 3 Comparison of the obtained light chain cDNA sequence of the anti-MVP Fab MVP-j4 (accession number AJ306837) with V-BASE. The Fab
uses a light chain belonging to the VL6 family. Highest homology was observed to germline clone 6a.366F5/V1-22...+. The antigen speciﬁc CDR3 sequences
for the light chain are: QSYSNNKWI. The number of amino acid changes from the germline, excluding the CDR3 region, is 10.
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Control
Figure 4 Western blots of cell lysates of MVP-overexpressing GLC4 ADR cells (A) and the immunoprecipitation products of the anti-MVP mouse Mab
LRP-56 (B; left lane) or a control Mab (B; right lane) from a cell lysate of the GLC4 ADR cells. Proteins were loaded, separated and blotted. Blots were
incubated with MVP-j4( A, left lane and B) or a control Fab (A, right lane) followed by HRP-labelled rabbit-anti-human lambda chain. Colour development
was with DAB/chloronaphthol/H2O2. On both blots, MVP-j4 was reactive with the MVP protein at the expected Mr of 110000 (arrow).
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reactive clone (Figure 1). Sequence analysis of six of these clones
conﬁrmed that they were all identical. One clone, named MVP-
j4, was used for further characterization studies. The sequences
of the heavy and light chain variable regions of the MVP-j4 clone
are available under accession numbers AJ306838 and AJ306837,
respectively, at the EMBL database.
Heavy and light chain usage of the anti-MVP Fab
Comparison of the obtained cDNA sequence of the anti-MVP Fab
with V-BASE showed that the Fab uses a heavy chain belonging to
the VH4 family and a light chain belonging to the VL6 family
(Figures 2 and 3). Highest homology was observed to germline
clones DP-66/V71–2...+ (heavy chain) and 6a.366F5/V1–22...+
(light chain). The antigen speciﬁc CDR3 sequences for the heavy
and light chain are: QGVYYYYGMDV and QSYSNNKWI, respec-
tively. The number of amino acid changes from the germline,
excluding the CDR3 region, is eight for the heavy chain and 10
for the light chain.
Reactivity of anti-MVP Fab in Western blots and
immunoprecipitation
In Western blots of cell lysates of MVP-overexpressing GLC4 ADR
cells, MVP-j4 was reactive with the MVP protein at the expected
Mr of 110000 (Figure 4A). Furthermore, MVP-j4 was able to detect
the Mr 110000 immunoprecipitation product of the anti-MVP
mouse Mab LRP-56 and a cell lysate of the GLC4 ADR cells in the
same test system (Figure 4B). Also, the recombinant MVP could
be detected in similar Western blot experiments (not shown).
In immunoprecipitation experiments, the anti-MVP Fab was
unable to precipitate the MVP protein from either MVP-over-
expressing GLC4 ADR cells or recombinant MVP in solution
(not shown). These results indicate that MVP-j4 is reactive to a
linear or more denatured epitope of the MVP molecule. Of note,
the LRP-56 mouse Mab is reactive to a more native epitope, judged
from its reactivity in the immunoprecipitation experiments (see
Figure 4B), and its inability to react with MVP in Western blots.
Also, LRP-56 is unreactive with recombinant MVP coated in ELISA
plates (not shown).
BIAcore analysis of anti-MVP Mabs and MVP-j4
The off-rates of several murine anti-MVP Mabs and MVP-j4 were
determined by surface plasmon resonance on a BIAcore 2000
instrument, with recombinant GST–MVP immobilised on the ﬂow
cell of a CM-5 sensorchip, giving a surface of 2000 resonance units.
As anticipated, the LRP-56 and LMR-5 Mabs were unreactive with
MVP presented in this way, but the other available (bivalent)
murine Mabs MVP-9, MVP-16, MVP-37, LRP were reactive with
the MVP molecule immobilised on the chip (Figure 5). These,
and the monovalent MVP-j4 human Fab, gave off-rates of
1.3610
73, 1.4610
72, 1.3610
74, 5.2610
75, and 1.3610
73,
s
71, respectively.
Reactivity of anti-MVP Fab on cytospins and tissue sections
A panel of cell lines with known presence or absence of MVP was
stained with MVP-j4. MVP-j4 was only very moderately reactive
on preparations of cell lines ﬁxed with 100% acetone. However,
using the guanidine ﬁxation method (see Materials and methods),
which facilitates detection of more denatured epitopes, the anti-
MVP Fab showed the presence of MVP in GLC4 ADR cells,
SW1573/2R120 cells and in an earlier identiﬁed small subpopula-
tion of cells of the MDR1 P-gp positive SW1573/2R160 cell line
(Figure 6A). Essentially similar results were obtained in control
stainings with MVP-37, using the same treatment, or with LRP-
56 Mab on acetone ﬁxed cytospins. Further conﬁrmation of the
speciﬁcity of the anti-MVP Fab was obtained in studying human
tissue staining. Using guanidine-treated, frozen sections of human
lung tissue, MVP-j4 was found to be reactive with MVP in the
epithelial cells of the bronchi (Figure 6B). Again, comparable stain-
ing results were seen in the control stainings with MVP-37 and
LRP-56.
DISCUSSION
For the detection of MVP and transmembrane transporter mole-
cules mediating MDR several conventionally produced murine
Mabs have become available. The phage display method allows
selection of human antibody fragments, which are expected to elicit
less or no immune responses when administered in humans. Using
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Figure 5 BIAcore analysis of the anti-MVP reagents. The off-rate of several murine anti-MVP Mabs and MVP-j4 was determined by surface plasmon
resonance on a BIAcore 2000 instrument, with recombinant GST-MVP immobilised on the ﬂow cell of a CM-5 sensorchip. The control Fab and LRP-
56 Mab (and LMR-5, not shown) were un-reactive in this system. The other murine Mabs MVP-9, MVP-16, MVP-37, LRP and the MVP-j4 human Fab
showed differential reactivity to the MVP molecule immobilised on the chip.
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MVP-37
GLC4 S GLC4 ADR SW1573/2R160 SW1573/2R120 A
B
MVP-f4
Control-Fab
MVP-37
Figure 6 Staining results for MVP in a panel of cell lines with known presence or absence of MVP (A) and in frozen sections of normal human lung (B).
Preparations were pretreated using the guanidine method (see Materials and methods) and stained with MVP-j4, control Fab or MVP-37 murine Mab.
Biotinylated rabbit-anti-mouse and HRP-labelled streptavidin were used as secondary reagents for the mouse Mab. For detection of the human Fabs,
9E10 Mab and HRP-labelled rabbit-anti-mouse serum was used. Colour development was with AEC/H2O2. Both the anti-MVP Fab MVP-j4 and the murine
Mab MVP-37 show, as expected, the presence of MVP in the GLC4 ADR cells, the SW1573/2R120 cells and in a characteristic low percentage of cells in the
MDR1 P-gp positive SW1573/2R160 cells (A). Furthermore, MVP-j4 and MVP-37 show the presence of MVP in the epithelial cells of the bronchi of the
lung (B).
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generated, and some of these have already entered phase III clinical
applications (Holliger and Hoogenboom, 1998; Vaughan et al,
1998). Up till now, for none of the molecules associated with
MDR these type of human antibodies have been generated. Only
for MDR1 P-gp humanised versions of the monoclonal antibodies
MRK16 (Hamada et al, 1990) and MRK17 (Ariyoshi et al, 1992)
have been constructed. Also, the phage display method has been
used successfully to identify peptide epitopes of MDR1 P-gp Mabs
(Poloni et al, 1995a,b) and peptides mimicking the drug-binding
activity of P-gp (Popkov et al, 1998). The present selection of a
human anti-MVP reactive Fab by the phage display method is,
therefore, the ﬁrst report on truly human antibodies in this ﬁeld.
During the selection steps of the anti-MVP Fab, successive selec-
tion rounds yielded increasing numbers of MVP-speciﬁc Fabs.
However, BstNI ﬁngerprint and sequence analyses showed that
eventually only one type of Fab was isolated. The selection of just
one type of Fab may have resulted from the way the selections were
performed, causing loss of low afﬁnity phages, e.g. due to low
amounts of antigen for selection and high stringency conditions
at the elution steps. Also, utilising recombinant MVP as the selec-
tion antigen, that may not have full native conformation, and the
apparent presence of selection-dominant epitopes in most antigens
(Hoogenboom et al, 1999) may have inﬂuenced the outcome of the
selections. On the other hand, although the presently used library
has been successfully applied for isolating Fabs against rare antigens
and self antigens (de Haard et al, 1999), it cannot be excluded that
these results still reﬂect library limitations.
In any case, the isolated MVP-j4 Fab performed very well in
several immunohistochemical and Western blot applications. The
immunohistochemical results were optimal when the cytospins
and tissues were pretreated with denaturing guanidine/HCl solu-
tion. These results, and the unreactivity of the Fab in
immunoprecipitation experiments, suggest its reactivity with a line-
ar epitope of the MVP molecule. Of note, both LRP-56 and LMR-5
Mabs are likely to react with more native epitopes, as judged from
their good performance in immunoprecipitation experiments, in
the absence of Western blot reactivity. Interestingly, BIAcore
analyses showed that the MVP-j4 Fab, as a monovalent fragment,
has a relatively slow off-rate (1.3610
73,s
71), as frequently
observed with conventional antibodies generated from a secondary
immune response. Indeed, the MVP-j4 Fab off-rate was within the
range observed for other (bivalent) murine anti-MVP Mabs.
The present identiﬁcation of an MVP-speciﬁc Fab may allow for
the construction of plasmids for functional knock-out purposes.
The cDNA encoding the Fab can be transferred to an eukaryotic
expression plasmid which may also provide a fusion between the
Fab and an endoplasmatic reticulum retention signal. Transfection
of this new construct into MVP-positive tumour cells then might
lead to blockage of the MVP protein, e.g. due to binding of the
Fab to the epitope during protein synthesis, and thus interfere with
vault assembly and/or function. Recently, the expression of only
the MVP molecule in Sf9 insect cells was shown to be sufﬁcient
for the assembly of vault-like particles (Stephen et al, 2001).
Targeting this critical vault component, therefore, is very likely
to result in the knock-out of functional vault particles. Analogous
applications of ‘intrabodies’ have already been described for e.g.
erbB-2 (Deshane et al, 1994), Ras (Lener et al, 2000), huntingtin
(LeCerf et al, 2001), as well as the anti-P-gp directed C219 ScFv
(Heike et al, 2001).
In conclusion, a human Fab fragment reactive to MVP, named
MVP-j4, was isolated by phage display technology. This Fab
may become a valuable tool in studying the contribution of
MVP and vaults to normal physiology and MDR.
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